Last reviewed 2026-08-25
This is the one goal on the site where peptides deliver decisively, and the reason is a specific class: GLP-1 receptor agonists and the dual agonists built on them. Semaglutide and tirzepatide are FDA-approved for chronic weight management with trial results in the 15 to 22 percent range — outcomes no previous weight-loss drug approached. The rest of the fat-loss peptide market is far weaker, and at least one popular compound failed to beat placebo in human trials.
Weight loss is the only goal here where the honest answer is straightforwardly positive. The incretin drugs changed obesity medicine, and the trial results are not marginal.
The gap on this page is therefore not between marketing and evidence — it is between the approved drugs and everything else sold alongside them. AOD-9604 has been marketed for fat loss for years despite failing to outperform placebo in human obesity trials. 5-Amino-1MQ has never been tested in a completed human trial at all.
The other live issue is legality. Compounded semaglutide and tirzepatide became widely available during the FDA shortage period, but the shortages were declared resolved and the enforcement discretion that permitted mass compounding ended. FDA has explicitly said that affordability and access do not constitute the clinical need that justifies compounding a commercially available drug.
Every entry carries the level of human evidence for this use — not the compound’s approval status for something else.
| Peptide | Evidence for this goal | FDA status | Typical cost/mo |
|---|---|---|---|
| Tirzepatide | FDA-approved for this use | FDA-approved | $250–$550 |
| Semaglutide | FDA-approved for this use | FDA-approved | $200–$500 |
| Liraglutide | FDA-approved for this use | FDA-approved | $350–$1350 |
| Orforglipron | FDA-approved for this use | FDA-approved | $350–$700 |
| Retatrutide | Human trials, not approved for this use | Research | $400–$900 |
| Survodutide | Human trials, not approved for this use | Research | Not published |
| Mazdutide | Human trials, not approved for this use | Research | Not published |
| Cagrilintide | Human trials, not approved for this use | Research | $300–$650 |
| Tesofensine | Human trials, not approved for this use | Research | Not published |
| AOD-9604 | No human evidence for this claim | Research | $150–$350 |
| 5-Amino-1MQ | Animal studies only | Research | Not published |
Dual GIP and GLP-1 receptor agonist; the most effective approved weight-loss medication.
The catch: Approved as Zepbound for weight management and Mounjaro for type 2 diabetes. Gastrointestinal side effects are common during dose escalation, and weight tends to return after stopping.
GLP-1 receptor agonist, once weekly.
The catch: Approved as Wegovy for weight management and Ozempic for diabetes. Same pattern of gastrointestinal effects and weight regain after discontinuation.
The original GLP-1 approved for weight management, dosed daily.
The catch: Roughly 8 percent weight loss — less than the weekly agents — but generic versions reaching the US market since 2024 can make it substantially cheaper.
Oral small-molecule GLP-1 agonist, no injection required.
The catch: Approved as Foundayo in April 2026 for chronic weight management in adults with obesity, or overweight with a weight-related condition, alongside diet and exercise. The first approved oral option in the class, which matters for anyone who will not inject.
Triple agonist of GLP-1, GIP and glucagon receptors; the most anticipated compound in the class.
The catch: Trial results have been striking, but it is investigational and no legitimate pharmacy dispenses it. Anything sold online as retatrutide is outside the legal supply chain entirely.
GLP-1 and glucagon dual agonist in phase 3.
The catch: Investigational, not approved anywhere, and cannot be legally prescribed or sold.
GLP-1 and glucagon dual agonist, approved in China.
The catch: Approval in China is not FDA review, and there is no lawful US supply route for it.
Amylin analogue, studied alongside semaglutide as the combination CagriSema.
The catch: Investigational. Its main interest is as a combination partner rather than alone.
Triple monoamine reuptake inhibitor repurposed for obesity.
The catch: Not a peptide, and mechanistically a stimulant rather than a metabolic drug. It can raise heart rate and blood pressure, and it is not FDA-approved.
Fragment of growth hormone marketed specifically as a fat-loss peptide.
The catch: This is the clearest example of the gap on this page. Its pivotal phase 2b obesity trial did not show statistically significant weight loss against placebo, and the available human evidence does not establish that it works for fat loss — yet it is still widely sold for exactly that purpose.
NNMT inhibitor sold for fat loss.
The catch: Reduced fat mass in obese mice. No completed human trial exists, so the safe dose and side effect profile in people are both unknown.
Tirzepatide, with up to roughly 22.5 percent mean weight loss in its trial programme, followed by semaglutide at roughly 15 percent. Both are FDA-approved for chronic weight management.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.
Tirzepatide requires a prescription and medical supervision. Each service below states that a licensed provider reviews your intake and prescribes through a US compounding pharmacy where appropriate. Those are the companies’ own descriptions of how they operate, not findings of ours. Compounded medications are not FDA-approved, and a consultation does not guarantee a prescription.
Some telehealth links below are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Commission never affects which products or clinics we list, how they are ordered, or what we say about them — see our editorial policy.
Says a board-certified physician reviews each intake and prescribes through a licensed 503A compounding pharmacy where appropriate, and lists a LegitScript certification. Compounded medications are not FDA-approved.
We are not a clinic and do not prescribe. Listing a service here is not a clinical endorsement of it, and you should confirm licensure and pharmacy sourcing yourself before treatment.
Tirzepatide, which produced up to roughly 22.5 percent mean body weight reduction in its trial programme, ahead of semaglutide at roughly 15 percent. Both are FDA-approved for chronic weight management, as are liraglutide and the oral agent orforglipron. Most compounds marketed for fat loss have no approval at all.
The FDA declared the semaglutide and tirzepatide shortages resolved and ended the enforcement discretion that allowed widespread compounding of copies. FDA has stated that cost and access do not by themselves establish the clinical need required to compound a commercially available drug. Compounding for a genuine individual clinical need remains narrower than the market that grew up during the shortage.
Its pivotal phase 2b obesity trial did not show statistically significant weight loss against placebo, and the human evidence overall does not establish weight-loss efficacy. It continues to be marketed for fat loss regardless, which makes it a useful test of whether a vendor is citing evidence or repeating claims.
Yes, typically. Trial extension data consistently shows substantial weight regain after discontinuation, which is why these are framed as treatments for a chronic condition rather than as a course you complete.
Our directory lists clinics whose own websites show they offer peptide therapy. We verify what each one actually provides rather than taking a listing at face value.
Browse the provider directory